Chugai Pharmaceutical Co., Ltd.
4519
Kedudukan dalam Saham
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Harga Saham
$41.60
Modal Pasaran
$68.46B
Perubahan (1 hari)
0.94%
Perubahan (1 tahun)
-12.56%
Negara
JP
Perdagangan Chugai Pharmaceutical Co., Ltd. (4519)
Kategori
Healthcare
Margin Operasi untuk Chugai Pharmaceutical Co., Ltd. (4519)
Margin Operasi pada October 2026 TTM: 47.24%
Menurut laporan kewangan dan harga saham terkini Chugai Pharmaceutical Co., Ltd., margin operasi semasa (TTM) ialah 47.24%. Pada akhir 2024, margin operasi syarikat ialah 46.46%.
Sejarah Margin Operasi untuk Chugai Pharmaceutical Co., Ltd. dari 2003 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | 47.24% | 0.68% |
| 2025 | 46.92% | 0.99% |
| 2024 | 46.46% | 24.22% |
| 2023 | 37.40% | -11.75% |
| 2022 | 42.38% | -2.31% |
| 2021 | 43.38% | 11.23% |
| 2020 | 39.00% | 24.76% |
| 2019 | 31.26% | 40.24% |
| 2018 | 22.29% | 15.61% |
| 2017 | 19.28% | 19.53% |
| 2016 | 16.13% | -9.43% |
| 2015 | 17.81% | 5.63% |
| 2014 | 16.86% | -11.22% |
| 2013 | 18.99% | -2.37% |
| 2012 | 19.45% | 16.40% |
| 2011 | 16.71% | -4.24% |
| 2010 | 17.45% | -9.40% |
| 2009 | 19.26% | 22.13% |
| 2008 | 15.77% | -18.46% |
| 2007 | 19.34% | 8.11% |
| 2006 | 17.89% | -26.07% |
| 2005 | 24.20% | 38.44% |
| 2004 | 17.48% | -4.74% |
| 2003 | 18.35% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 49.72% | -98.95% |
US
|
|
| 25.70% | -99.46% |
US
|
|
| 29.32% | -99.38% |
US
|
|
| 16.65% | -99.65% |
US
|
|
| 26.59% | -99.44% |
CH
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.